Editas Medicine, Inc.
For the period ended Mar 31, 2026. Filed May 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 5, 2026
EDIT$2.51-8.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity for the
Condensed Consolidated Statements of Stockholders’ Equity
(amounts in thousands, except share data)
| Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensiveIncome (Loss) · AccumulatedDeficit · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance at December 31, 2025 | 97,866,996 | $10 | $1,655,781 | $— | $(1,628,503) | $27,288 |
| Vesting of restricted common stock awards | 34,038 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 2,102 | — | — | 2,102 |
| Net loss | — | — | — | — | (24,982) | (24,982) |
| Balance at March 31, 2026 | 97,901,034 | $10 | $1,657,883 | $— | $(1,653,485) | $4,408 |
| Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensiveLoss · AccumulatedDeficit · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance at December 31, 2024 | 82,734,696 | $8 | $1,602,441 | $268 | $(1,468,443) | $134,274 |
| Issuance of common stock from at-the-market equity offering, net | 706,236 | — | 1,435 | — | — | 1,435 |
| Vesting of restricted common stock awards | 268,604 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 2,979 | — | — | 2,979 |
| Unrealized loss on marketable debt securities | — | — | — | (180) | — | (180) |
| Net loss | — | — | — | — | (76,088) | (76,088) |
| Balance at March 31, 2025 | 83,709,536 | $8 | $1,606,855 | $88 | $(1,544,531) | $62,420 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.